Targovax ASA: Invitation to investor call
Oslo, Norway, 21 January 2020 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, invites to an investor and analyst call Wednesday 22 January 2020 at 08:30 CET regarding the first set of clinical results from the randomized phase I/II trial of ONCOS-102 in combination with standard of care chemotherapy in malignant pleural mesothelioma. Time: 08:30 CETCompany representatives: Øystein Soug, CEO, Dr. Magnus Jäderberg, Chief Medical Officer and Torbjørn Furuseth, CFOLanguage: NorwegianFormat: